Table 3 |
||||
|
Changes in body composition and bone mineral density between 3 and 24 months |
||||
|
P value |
||||
|
|
||||
|
Treatment A (n = 14) |
Treatment B (n = 11) |
Time |
Treatment × Compliance × Time |
|
|
|
||||
|
Body mass index (kg/m2) |
0.54 (-0.37 to 1.44) |
0.89 (-0.13 to 1.91) |
0.07 |
0.37 |
|
Fat mass (kg) |
0.36 (-1.54 to 2.25) |
3.77 (1.63 to 5.90) |
0.028 |
0.040 |
|
Fat mass index (kg/m2) |
0.05 (-0.62 to 0.72) |
1.24 (0.48 to 2.00) |
0.035 |
0.035 |
|
Fat (%) |
0.15 (-2.03 to 1.73) |
2.80 (0.67 to 4.91) |
0.11 |
0.17 |
|
Trunk/peripheral fat ratio |
0.15 (-0.05 to 0.36) |
0.18 (-0.05 to 0.42) |
0.18 |
0.82 |
|
Trunk fat (kg) |
-0.01 (-1.26 to 1.25) |
1.11 (-1.95 to 4.17) |
0.40 |
0.36 |
|
Lean body mass (kg) |
1.12 (-0.06 to 2.30) |
0.52 (-0.81 to 1.86) |
0.007 |
0.79 |
|
Appendicular lean mass (kg) |
0.08 (-0.65 to 0.80) |
0.25 (-0.56 to 1.07) |
0.26 |
0.83 |
|
Fat-free mass |
1.23 (0.08 to 2.38) |
0.57 (-0.73 to 1.87) |
0.004 |
0.69 |
|
Fat-free mass index |
0.29 (-0.15 to 0.72) |
0.16 (-0.33 to 0.65) |
0.011 |
0.63 |
|
L2 to L4 |
||||
|
BMD (g/cm2) |
0.02 (-0.01 to 0.05) |
0.03(0.00 to 0.06) |
0.15 |
0.56 |
|
Z score |
0.31 (0.06 to 0.57) |
0.29 (0.00 to 0.58) |
0.030 |
0.26 |
|
T score |
0.26 (-0.03 to 0.55) |
0.26 (-0.03 to 0.55) |
0.20 |
0.55 |
|
BMD (g/cm2) |
0.00 (-0.02 to 0.02) |
0.01 (-0.03 to 0.01) |
0.19 |
0.63 |
|
Z score |
0.12 (-0.06 to 0.30) |
0.04 (-0.24 to 0.17) |
0.24 |
0.63 |
|
T score |
0.01 (-0.14 to 0.17) |
0.12 (-0.29 to 0.06) |
0.20 |
0.32 |
|
|
||||
|
Changes in body composition and bone mineral density (BMD) between 3 and 24 months, using a mixed linear model. Data presented as mean (95% confidence interval). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. Changes between 3 and 12 months and patients not compliant to respective treatment are not presented. P values given for the interactions with the main factor Time and the interactions with factor Time. Bold values are statistically significant. |
||||
|
Engvall et al. Arthritis Research & Therapy 2010 12:R197 doi:10.1186/ar3169 |
||||
